Michael J. Hansen

Mayo Clinic — United States

Medicine · Health Sciences

19h-index3.1kcitations132works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(64), Phagocytosis and Immune Regulation(33), Immunotherapy and Immune Responses(24), Cancer Immunotherapy and Biomarkers(14), T-cell and B-cell Immunology(13)

Publications132 total

Supplementary Table S1 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025Open Access
Supplementary Figure Legends from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025Open Access
Supplementary Figures from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025Open Access
Supplementary Table S2 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025Open Access
Supplementary Figure 1 from Anti–PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I Expression
2025Open Access
Activation of antiviral CD8 T resident memory cells induces BBB disruption and promotes a shift from active to passive anxiety-like behavior 4340
The Journal of Immunology·2025Open Access
Mitigating off target B cell transduction during in situ CAR T cell induction 3591
The Journal of Immunology·2025Open Access
Induced Proteinuria Enhances Adeno-Associated Virus Transduction of Renal Tubule Epithelial Cells After Intravenous Administration
2025· 1 citedOpen Access
Heightened effector immune cell infiltration of the hippocampus concurrently with brain ventricular volume expansion in aged APP/PS1 mice
Journal of Neuroimmunology·2025
MHC class II-mediated spontaneous rejection of breast carcinomas expressing model neoantigens
Journal for ImmunoTherapy of Cancer·2025· 2 citedOpen Access
Supplementary Figure Legends from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Figure Legends from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Table S1 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Figures from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Figure 1 from Anti-PD-1 and extended half-life-IL-2 synergize for treatment of murine glioblastoma independent of host MHC Class I expression
2024Open Access
Supplementary Table S1 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Table S2 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Table S2 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Figures from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Data from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
page 1 of 7Next →

Frequent Co-authors

Aaron J. Johnson(15), Reona Sakemura(13), Michelle J. Cox(13), Mehrdad Hefazi(13), Kendall J. Schick(13), Neil E. Kay(13), Saad S. Kenderian(13), Larry R. Pease(12), Roman H. Khadka(10), Fang Jin(10), Katayoun Ayasoufi(10), Claudia Manriquez Roman(9), Erin E. Tapper(9), Michael W. Ruff(9), Sameer A. Parikh(9), Wendy K. Nevala(7), Courtney S. Malo(7), Paulina Horvei(6), Emma N. Goddery(6), Cori E. Fain(6)